NEWS

Congratulations to Dr. Philipp Spycher, finalist for the Swiss Technology Award 2017 (Category «Inventors»)!

More Information
Presentation of the projects in the category "Inventors"


Congratulations to Dr. Cristina Müller, winner of the Ruzicka Prize 2014!

More Information



Mit Vitamin gegen Krebs

Forschung mit radioaktiv markierten Folsäure-Verbindungen
Täglich nehmen wir mit unserer Nahrung Folsäure auf. Dieses Vitamin ist wichtig für die Zellteilung und somit für das Wachstum. Doch in Zukunft könnte dem Vitamin noch eine weitere Rolle zukommen. Denn am PSI werden Therapien gegen Krebs entwickelt, die Folsäure nutzen.
Weitere Information


BetaCure

The Center Radiopharmaceuticals Sciences is a member of the FP7 consortium “BetaCure”, a collaboration between 17 research institutions and companies throughout whole Europe. The aim of the project “Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology” is to develop new treatment modalities for rare beta-cell derived hyperinsulinemic diseases like Nesidioblastosis or Insulinoma. Nesidioblastosis is a hyperplasia of the beta-cells which lead to a hyperproduction of insulin in newborns. Insulinomas are tumors derived from beta-cells. These diseases are potential life threatening because of its hypoglycemic pattern and have only limited therapeutic modalities. The consortium is clinical oriented with a strong part of preclinical research and has a close collaboration with patient organizations related to these diseases. The project started on 1st of April 2014.


Development of radiolabeled antibodies for clinical diagnosis of invasive Aspergillosis by PET imaging

The Center for Radiopharmaceutical Sciences is a research partner in the project entitled “New Molecular-Functional Imaging Technologies and Therapeutic Strategies for Theranostic of Invasive Aspergillosis” (MATHIAS) funded by the European Union in the 7th Framework Programme. The main goal of this collaborative project is the development of radiolabeled antibodies for clinical diagnosis of invasive Aspergillosis by PET imaging. The preclinical evaluation of different antibody fragments for imaging and radioimmunotherapy are additional goals of MATHIAS. The project started on 1st October 2013 and the duration of the project is five years.
More Information


Awards

Cancer Network Zurich-Cancer Biology Ph.D. Program Travel Grant:
The Cancer Biology Ph.D. Program awarded a travel grant to NASTASSJA TERRANEO to visit the 25th Annual Meeting of AGRR 2017 in Munich.

SIMON KÄPPELI also received a travel grant in 2017 to work with Professor Martin Gotthardt at the Radboud University Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, Netherlands on a BetaCure project

European Society for Molecular Imaging 2016 Poster Award:
First Price awarded to NICHOLAS VAN DER MEULEN (Radionuclide Development.
EMIM Poster Prize 2016.pdf
Poster Abstract



Ruzicka-Prize 2014:
One of the most important awards for young investigators in the field of chemistry in Switzerland was awarded to Dr. CRISTINA MÜLLER. She received the Ruzicka-Prize in 2014 for her work in the field of radiopharmaceutical sciences, in which scandium radionuclides for diagnosis and therapy of cancer diseases have been studied preclinically for the first time.
Further information: ETH-Medienmitteilung
Further information: ETH-Flyer: Ruzicka-Prize 2014

Swiss Pharma Science Day 2014 Poster Award:
First Prize awarded to STEPHANIE HALLER (Nuclide Chemistry).
Artikel zum Posterpreis 2014 in: pharmaJournal 23 | 11.2014
Poster Abstract

Swiss Pharma Science Day 2013 Poster Award:
First Prize awarded to STEPHANIE HALLER (Nuclide Chemistry).
Poster Abstract